GKOS · Glaukos Corporation
$167.25
-1.84% last session
End-of-day data · close of 2026-09-11
Market cap
$10B
Enterprise value
$10B
Trailing P/E
—
Forward P/E
337.8
Dividend yield
—
Beta
0.77
Avg volume
1M
Employees
1K
Daily Change %
-1.84%
5 Days Change
1.31%
10 Days Change
0.13%
30 Days Change
-1.21%
60 Days Change
17.73%
Month to Day Change
1.75%
Year to Day Change
59.23%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — GKOS
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-08-20
Latest call per bank · past 12 months
UBS
Neutral$172
+1.0% vs priceCitigroup
Buy$188
+10.3% vs priceWells Fargo
Overweight$178
+4.5% vs priceJP Morgan
Overweight$140
-17.8% vs priceGoldman Sachs
Buy$103
-39.5% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-08-20 | BTIG | Maintains | Buy | $193 → $202 |
| 2026-07-30 | UBS | Maintains | Neutral | $150 → $172 |
| 2026-07-30 | HC Wainwright & Co. | Maintains | Buy | $168 → $195 |
| 2026-07-30 | Citigroup | Maintains | Buy | $175 → $188 |
| 2026-07-30 | Piper Sandler | Reiterates | Overweight | $165 → $195 |
| 2026-07-30 | Stifel | Maintains | Buy | $175 → $190 |
| 2026-07-30 | Truist Securities | Maintains | Buy | $180 → $215 |
| 2026-07-30 | Wells Fargo | Maintains | Overweight | $138 → $178 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 40 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.3% below the 50-day MA ($169.44).
- Price vs 200-day MA: Trading 27.7% above the 200-day MA ($130.94).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-2.47) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($74.67) and high ($189.55).
GKOS Price Chart
Loading chart for GKOS…
Fundamentals
About Glaukos Corporation
Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, develops therapies for the treatment of glaucoma, corneal disorders, and retinal diseases in the United States and internationally. It offers iStent and iStent inject W micro-bypass stents designed to treat mild-to-moderate open-angle glaucoma through the restoration of the natural physiologic outflow pathways for aqueous humor. The company also provides iStent infinite indicated for use in the treatment of patients with glaucoma uncontrolled by prior medical and surgical therapy; and iDose TR, an intracameral procedural pharmaceutical therapy indicated for the reduction of intraocular pressure in patients with open-angle glaucoma or ocular hypertension. In addition, the company develops iLink, a device used for the treatment of keratoconus without the removal of the epithelium; ILution, a platform of cream-based drug formulation applied to the outer surface of the eyelid for drop less transdermal delivery of pharmaceutically active compounds for the treatment of anterior segment eye disorders; and retinal XR platform to treat age-related macular degeneration, diabetic macular edema, retinal vein occlusion, and other posterior segment retinal diseases. It sells its products to ambulatory surgery centers, hospitals, and physician private practices through a direct sales organization, direct sales subsidiaries, and distributors. The company was formerly known as Transdx, Inc. Glaukos Corporation was incorporated in 1998 and is headquartered in Aliso Viejo, California.
More in Medical Devices
ABT
Abbott Laboratories
$179B -14.4% YTD
MDT
Medtronic plc.
$117B -2.7% YTD
SYK
Stryker Corporation
$104B -21.2% YTD
BSX
Boston Scientific Corporation
$62B -52.8% YTD
EW
Edwards Lifesciences Corporatio
$50B 1.1% YTD
DXCM
DexCom, Inc.
$32B 26.4% YTD
GEHC
GE HealthCare Technologies Inc.
$29B -20.4% YTD
PHG
Koninklijke Philips N.V. NY Reg
$24B -4.0% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.